Neodymium Laser Treatment of IOP Rise Following Ex-Press Glaucoma Device Implantation: A Retrospective Review From 4 Institutions.


Journal

Journal of glaucoma
ISSN: 1536-481X
Titre abrégé: J Glaucoma
Pays: United States
ID NLM: 9300903

Informations de publication

Date de publication:
Feb 2020
Historique:
pubmed: 11 12 2019
medline: 21 3 2020
entrez: 11 12 2019
Statut: ppublish

Résumé

PRéCIS:: Our retrospective study examined the use of neodymium laser in 53 eyes with high intraocular pressure (IOP) following Ex-Press filtration device implantation. We found a statistically significant immediate IOP-lowering effect in all eyes, with a mean IOP reduction of 13.34±8.99 mm Hg, and a posttreatment IOP of 14.30±8.57 mm Hg (P<0.0001). Of a subset of 43 eyes on which 6 months follow-up IOP data was available, 28 eyes achieved treatment success (IOP<18 without further surgical interventions) with a mean IOP of 11.39±4.03 mm Hg at 6 months. The purpose of this study was to report on the use of neodymium laser for treatment of eyes with IOP rise following Ex-Press glaucoma filtration device implantation. We retrospectively examined the medical records of 73 patients who underwent Ex-Press device implantation at 4 medical institutions between 2007 and 2015 and subsequently developed an IOP rise. Enrollment criteria included patients with POAG on whom posttreatment IOP data is available. Indications for treatment with neodymium laser were an IOP above target and a flat bleb. To disrupt the presumed microblockage, the neodymium laser was aimed at the axial and relief ports of the Ex-Press device. Applanation tonometry measurements were followed up after neodymium treatment for variable time intervals. Success was defined as an IOP <18 mm Hg at 6 months without further surgical or laser-based glaucoma interventions. A total of 73 charts were reviewed. Twenty patients were excluded due to insufficient data or a diagnosis other than POAG. Data from 53 eyes of the remaining 53 patients was analyzed. The mean duration between Ex-Press implantation and rise in IOP requiring neodymium intervention was 34.2 months (range, 1.1 to 67.2). We found a statistically significant immediate IOP-lowering effect in all eyes, with a mean IOP drop of 13.34±8.99 mm Hg, and a mean posttreatment IOP of 14.30±8.57 mm Hg (P<0.0001). Of a subset of 43 eyes on which 6 months follow-up IOP data was available, 11 eyes required further glaucoma intervention (surgery or laser-based); 4 eyes had an IOP of ≥18 at 6 months. In the remaining 28 successful eyes, a sustained IOP<18 mm Hg was observed at 6 months, with a mean pressure of 11.39±4.03 mm Hg (P<0.0001). Hypotony (IOP<5) occurred in 3 eyes immediately following treatment and self-resolved by 1 week. Our retrospective case series suggests that neodymium laser is a potential consideration in eyes with sustained IOP rise after Ex-Press device implantation.

Identifiants

pubmed: 31821183
doi: 10.1097/IJG.0000000000001423
pii: 00061198-202002000-00004
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

92-96

Références

Maris PJ, Ishida K, Netland PA. Comparison of trabeculectomy with Ex-Press miniature glaucoma device implanted under scleral flap. J Glaucoma. 2007;16:14–19.
Dahan E, Ben Simon GJ, Lafuma A. Comparison of trabeculectomy and Ex-Press implantation in fellow eyes of the same patient: a prospective, randomized study. Eye. 2012;26:703–710.
Netland PA, Sarkisian SR Jr, Moster MR, et al. Randomized, prospective, comparative trial of Ex-Press glaucoma filtration device versus trabeculectomy (XVT study). Am J Ophthalmol. 2014;157:433.e3–440.e3.
Wang W, Zhang X. Meta-analysis of randomized controlled trials comparing EX-PRESS implantation with trabeculectomy for open-angle glaucoma. PLoS One. 2014;9:e100578.
Beltran-Agullo L, Trope GE, Jin YP, et al. Comparison of visual recovery following Ex-PRESS versus trabeculectomy: results of a prospective randomized controlled trial. J Glaucoma. 2015;24:181–186.
Kanner EM, Netland PA, Sarkisian SR, et al. Ex-Press miniature glaucoma device implanted under a scleraflap alone or combined with phacoemulsification cataract surgery. J Glaucoma. 2009;18:488–491.
Traverso CE, De Feo F, Messas-Kaplan A, et al. Long term effect on IOP of a stainless steel glaucoma drainage implant (Ex-Press) in combined surgery with phacoemulsification. Br J Ophthalmol. 2005;89:425–429.
De Feo F, Bagnis A, Bricola G, et al. Efficacy and safety of a steel drainage device implanted under a scleral flap. Can J Ophthalmol. 2009;44:457–462.
Stewart RM, Diamond JG, Ashmore ED, et al. Complications following Ex-Press glaucoma shunt implantation. Am J Ophthalmol. 2005;140:340–341.
Rivier D, Roy S, Mermoud A, et al. Ex-Press R-50 miniature glaucoma implant insertion under the conjunctiva combined with cataract extraction. J Cataract Refract Surg. 2007;33:1946–1952.
Zalta AH, Sweeney CP, Zalta AK, et al. Intracameral tissue plasminogen activator use in a large series of eyes with valved glaucoma drainage implants. Arch Ophthalmol. 2002;120:1487–1493.
Tanito M, Sano I, Ohira A. A case report of progressive obstruction of Ex-Press miniature glaucoma shunt after transient flat anterior chamber and treatment using neodymium laser. BMC Ophthalmol. 2015;15:2.
Bagnis A, Papadia M, Scotto R, et al. Obstruction of the Ex-Press miniature glaucoma device: Nd: neodymium laser as a therapeutic option. J Glaucoma. 2011;20:271.
De Feo F, Jacobson S, Nyska A, et al. Histological biocompatibility of a stainless steel miniature glaucoma drainage device in humans: a case report. Toxicol Pathol. 2009;37:512–516.

Auteurs

Majd Mustafa (M)

Department of Ophthalmology, McGill University, Montreal, QC.

Nir Shoham-Hazon (N)

Department of Ophthalmology and Visual Sciences, Dalhousie University, Miramichi, NB.

George R Reiss (GR)

Eye Physicians and Surgeons of Arizona, Phoenix, AZ.

Thomas W Samuelson (TW)

Minnesota Eye Consultants, Minneapolis, MN.

Gary Condon (G)

Coastal Eye Institute, Sarasota, FL.

Iqbal Ike K Ahmed (IIK)

Prism Eye Institute, Mississauga, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH